Results 161 to 170 of about 885,465 (288)

The Effect of Hypoxia on Relative Biological Effectiveness and Oxygen Enhancement Ratio for Cells Irradiated with Grenz Rays. [PDF]

Cancers (Basel), 2022
Chan CC, Chen FH, Hsueh KL, Hsiao YY.
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Relative biological effectiveness for epithermal neutron beam contaminated with fast neutrons in the linear accelerator-based boron neutron capture therapy system coupled to a solid-state lithium target. [PDF]

J Radiat Res, 2023
Nakamura S, Imamichi S, Shimada K, Takemori M, Kanai Y, Iijima K, Chiba T, Nakayama H, Nakaichi T, Mikasa S, Urago Y, Kashihara T, Takahashi K, Nishio T, Okamoto H, Itami J, Ishiai M, Suzuki M, Igaki H, Masutani M.   +19 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Estimation of relative biological effectiveness of ²²⁵Ac compared to ¹⁷⁷Lu during [²²⁵Ac]Ac-PSMA and [¹⁷⁷Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS. [PDF]

EJNMMI Phys, 2023
Rumiantcev M, Li WB, Lindner S, Liubchenko G, Resch S, Bartenstein P, Ziegler SI, Böning G, Delker A.   +8 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Relative Biological Effectiveness-Clinical Practice at US Proton Therapy Centers. [PDF]

Int J Part Ther
Lühr A, Mohan R, Mahajan A, Shih HA, Paganetti H.   +4 more
europepmc   +1 more source

The relative biological effectiveness of 160 MeV protons [PDF]

, 1978
Hall, E. J., Kellerer, Albrecht M., Lam, Y.-M. P., Rossi, H. H.   +3 more
core  

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

A computational method to estimate the relative biological effectiveness and tumor control probability for low-LET proton irradiations. [PDF]

PLoS One
Chan CC, Hsueh KL, Lai CY, Hsiao YY.
europepmc   +1 more source